BioSpace News Archive

BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it is hosting a webinar at 11 a.m. ET on March 4 that will describe how primary hepatocytes are being used to screen small molecule drugs for activity against the Plasmodium parasites that cause malaria.

Endo International plc (NASDAQ: ENDP) today reported financial results for the fourth-quarter and full-year ended December 31, 2020 and introduced 2021 financial guidance.

Fusion Robotics LLC, a spinal robotics and navigation company today announced receiving 510(k) clearance to market their 3D imaging compatible navigation and robotic targeting system for spine surgery in the U.S. market.

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter has agreed to purchase on a firm commitment basis 546,875 common shares of Edesa, at a price to the public of $6.40 per share, less underwriting discounts and commissions.

The Muscular Dystrophy Association (MDA) today celebrated the decision by the US Food and Drug Administration (FDA) to grant accelerated marketing approval to casimersen (Amondys 45) for the treatment of Duchenne muscular dystrophy (DMD) in patients amenable to skipping exon 45.

Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that Chairman, Chief Executive Officer and President, Kevin Hrusovsky, will be delivering a virtual presentation at the Cowen 41st Annual Health Care Conference on Wednesday, March 3, at 11:00 a.m. EST.

CANbridge Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing drug candidates in China and North Asia, and Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, have agreed to terminate their 2018 license agreement, in which Puma granted CANbridge exclusive rights to develop and commercialize NERLYNX

Harbour BioMed (HBM) (HKEX: 02142) today announced that the China National Medical Products Administration (NMPA) has approved its Investigational New Drug (IND) application for HBM4003, the next generation anti-CTLA-4 antibody in combination with PD-1 antibody/chemotherapy for the treatment of patients with advanced NSCLC and solid tumors.

Extendicare Inc. reported results for the three and twelve months ended December 31, 2020.

Merck Animal Health, known as MSD Animal Health outside the United States and Canada, a division of Merck & Co., Inc., Kenilworth, N.J., USA, announced the completion of its acquisition of PrognostiX Poultry Limited d/b/a Poultry Sense Ltd. from its founding shareholders.